Clinical and preclinical pulmonary disease in newly diagnosed rheumatoid arthritis: a two-year follow-up study

Hyldgaard, Charlotte; Harders, Stefan Walbom; Blegvad, Jesper; Herly, M.; Mašić, Dženan; Sofíudóttir, B K; Urbonavičienė, Gražina; Andersen, Frederikke D.; Isaksen, Christin; Løgstrup, Brian Bridal; Ellingsen, Torkell

doi:10.1080/03009742.2023.2194105

Cited by 4 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with rheumatoid arthritis (RA) are at risk of developing interstitial lung disease (ILD). The reported prevalence of ILD in patients with RA varies widely depending on the population studied and the criteria used to define ILD, with estimates ranging between 2% and 41% [1][2][3][4][5][6]. RA-ILD confers a substantially increased risk of mortality [4,[7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Design of ANCHOR-RA: a multi-national cross-sectional study on screening for interstitial lung disease in patients with rheumatoid arthritis

Sparks,

Dieudé,

Hoffmann-Vold

et al. 2024

BMC Rheumatol

View full text Add to dashboard Cite

Background Patients with rheumatoid arthritis (RA) are at risk of developing interstitial lung disease (ILD), which is associated with high mortality. Screening tools based on risk factors are needed to decide which patients with RA should be screened for ILD using high-resolution computed tomography (HRCT). The ANCHOR-RA study is a multi-national cross-sectional study that will develop a multivariable model for prediction of RA-ILD, which can be used to inform screening for RA-ILD in clinical practice. Methods Investigators will enrol consecutive patients with RA who have ≥ 2 of the following risk factors for RA-ILD: male; current or previous smoker; age ≥ 60 years at RA diagnosis; high-positive rheumatoid factor and/or anti-cyclic citrullinated peptide (titre > 3 x upper limit of normal); presence or history of certain extra-articular manifestations of RA (vasculitis, Felty’s syndrome, secondary Sjögren’s syndrome, cutaneous rheumatoid nodules, serositis, and/or scleritis/uveitis); high RA disease activity in the prior 12 months. Patients previously identified as having ILD, or who have had a CT scan in the prior 2 years, will not be eligible. Participants will undergo an HRCT scan at their local site, which will be assessed centrally by two expert radiologists. Data will be collected prospectively on demographic and RA-related characteristics, patient-reported outcomes, comorbidities and pulmonary function. The primary outcomes will be the development of a probability score for RA-ILD, based on a multivariable model incorporating potential risk factors commonly assessed in clinical practice, and an estimate of the prevalence of RA-ILD in the study population. It is planned that 1200 participants will be enrolled at approximately 30 sites in the USA, UK, Germany, France, Italy, Spain. Discussion Data from the ANCHOR-RA study will add to the body of evidence to support recommendations for screening for RA-ILD to improve detection of this important complication of RA and enable early intervention. Trial registration clinicaltrials.gov NCT05855109 (submission date: 3 May 2023).

show abstract

Section: Introductionmentioning

confidence: 99%

“…A recent meta-analysis of data from 15 studies in patients with RA-ILD found a mortality rate of 49% over 5 to 10 years [12]. Patients with RA may also have other respiratory complications such as pleural disease [13], bronchiectasis [6,14] or emphysema [6,15].…”

Section: Introductionmentioning

confidence: 99%

Design of ANCHOR-RA: a multi-national cross-sectional study on screening for interstitial lung disease in patients with rheumatoid arthritis

Sparks,

Dieudé,

Hoffmann-Vold

et al. 2024

BMC Rheumatol

View full text Add to dashboard Cite

show abstract

Clinical Course of Interstitial Lung Disease in Patients With Rheumatoid Arthritis

Matteson,

Bendstrup,

Strek

et al. 2024

ACR Open Rheumatology

View full text Add to dashboard Cite

Interstitial lung disease (ILD) is a frequent manifestation of rheumatoid arthritis (RA) that is associated with high mortality. RA‐ILD may initially be asymptomatic, and lung function may be markedly impaired by the time it is diagnosed. The course of RA‐ILD is highly variable, with some patients experiencing no discernable progression or a slow decline, whereas others experience more rapid deterioration. Some patients develop progressive pulmonary fibrosis, which is associated with high mortality. Although risk factors for the progression of RA‐ILD have been identified, including older age, worse lung function, and a usual interstitial pneumonia pattern on high‐resolution computed tomography, it is not possible to predict the course of RA‐ILD in an individual patient. The association between RA disease activity and progression of RA‐ILD remains unclear. Regular monitoring is important to enable the prompt identification of progression and early intervention to preserve lung function. The management of RA‐ILD requires a multidisciplinary and individualized approach, taking account of the severity and progression of articular and lung disease, risk factors for the progression of RA‐ILD, and the patient's preferences, and may include immunosuppression, antifibrotic therapy, and supportive care.

show abstract

Risk profiles for rheumatoid arthritis-associated interstitial lung disease in a cohort of patients with five-year follow-up

Hyldgaard,

Blegvad,

Sofiudóttir

et al. 2024

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

Clinical and preclinical pulmonary disease in newly diagnosed rheumatoid arthritis: a two-year follow-up study

Cited by 4 publications

References 42 publications

Design of ANCHOR-RA: a multi-national cross-sectional study on screening for interstitial lung disease in patients with rheumatoid arthritis

Design of ANCHOR-RA: a multi-national cross-sectional study on screening for interstitial lung disease in patients with rheumatoid arthritis

Clinical Course of Interstitial Lung Disease in Patients With Rheumatoid Arthritis

Risk profiles for rheumatoid arthritis-associated interstitial lung disease in a cohort of patients with five-year follow-up

Contact Info

Product

Resources

About